Biological Changes Associated With High Risk of Preeclampsia in Nulliparous Women

Brief summary (registry, in English)

Primary outcome 1. to identify biological changes in nulliparous women at high risk for preeclampsia defined by combined screening by Fetal Medicine Foundation (FMF) 2. to identify biological effects of aspirin in nulliparous women with high risk for preeclampsia Secondary outcomes include findings of longitudinal development and predictive potential of biological markers associated with high-risk for preeclampsia and aspirin treatment. The main questions it aims to answer are: * Is high risk for preeclampsia associated with biological changes during pregnancy? * How does aspirin modulate the biological changes associated with high risk for preeclampsia? Nulliparous women will undergo routine clinical care at two regional hospitals with different treatment strategies, and selected to the study in three groups: low risk of preeclampsia, high risk of preeclampsia without aspirin, and high-risk of preeclampsia with aspirin treatment.

What you commit to

• Study type: Observational
• Planned participants: 200
• From 22 May 2024 to the primary completion date, 31 Dec 2026
• 2 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.